Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

Phase 2 clinical trial in patients with ovarian cancer. SNS-032, Sunesis' potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and receptor tyrosine kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595 and SNS-032 and planned additional clinical testing and development efforts. Words such as "look forward," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risk
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 DiaperBuys, a national online ... Aging’ Month this September. Healthy Aging Month was started ... the nation on the positive aspects of growing older. ... conditions or side effects from medications that cause urinary ... Manager for DiaperBuys.com. “This can seem daunting to some ...
(Date:9/16/2014)... 16, 2014 Banish headaches forever with ... approved Cefaly device for chronic migraine relief and treatment. ... the United States. Until now, US patients would directly ... in Belgium and wait 2-3 weeks for their device ... United States and once prescription and payment is received, ...
(Date:9/16/2014)... Reading, MA (PRWEB) September 16, 2014 ... announce its partnership with Fairfax Egg Bank. The collaboration ... and expand the donor egg offering at the Fertility ... operated since 2006 and offers the nation’s largest selection ... is advantageous for several reasons:, , ...
(Date:9/15/2014)... (PRWEB) September 16, 2014 The team ... Carey Danis & Lowe report that the ... was found responsible for the injuries that a woman ... to treat stress urinary incontinence (SUI). , Carey Danis ... medical device litigation and personal injury law. The St. ...
(Date:9/15/2014)... 2014 Hastings and Hastings, an experienced ... announces one flat attorney fee for personal injury cases. ... the largest portion possible of their settlement or recovery ... and damaged personal property. In addition, Hastings and Hastings ... simply states that no fees are due unless a ...
Breaking Medicine News(10 mins):Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
... , SAN BERNARDINO, Calif., Aug. 11 ... its customers and employees recently raised $266,429.00 to benefit the Leukemia ... has raised over $460,000 for this organization. , , ... the month of June 2009, Stater Bros., customers and employees at ...
... , WASHINGTON, Aug. 11 Even while ... is showing hospitals owned and operated by physicians among the best in the ... of "healthcare reform." , , The independent testing and research ... patients around the country. Overwhelmingly, Cons u mer ...
... Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... the U.S. Food and Drug Administration,s (FDA) complete response ... trazodone. , As previously announced, Labopharm received a complete ... indicating the Company,s new drug application (NDA) for its ...
... public survey conducted in Europe found that the vast ... and prostate cancer screening, according to a new study ... the National Cancer Institute . Gerd Gigerenzer, of ... and colleagues conducted a survey of over 10,200 people ...
... , , , , ... SCOR ), a leader in measuring the digital world, today ... the effects of increasing U.S. unemployment on online consumer activity. While ... substantial declines, there has been a corresponding increase in the number ...
... Healthcare reform has become a hot button issue for politicians and ... clear the air and separate fact from fiction. , , ... e QtY97yVQFUg6so , , ... and unrestricted use at http://www.medi a ...
Cached Medicine News:Health News:Stater Bros. Raises $266,429.00 for the Leukemia & Lymphoma Society 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 3Health News:Labopharm submits response to FDA for novel antidepressant 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
(Date:9/15/2014)... MINNEAPOLIS , Sept. 15, 2014 ... a non-profit professional association serving more than 4,500 ... released its 2015 SCALENDAR, which chronicles corporate fines ... compliance and ethics professionals have a ready reference ... "We developed the SCALENDAR to help ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 2012 Mylan Inc. (Nasdaq: MYL ) today announced its ... Financial Results Adjusted diluted EPS of ... for the same prior year period, an increase of 18%; ... 31, 2011 compared to $1.61 for the prior year, an increase of ...
... CITY, N.J., Feb. 21, 2012 S1 Pharmaceuticals, Inc. ... New Drug (IND) application to the U.S. Food and ... (Lorexys).  Lorexys is the Company,s lead drug candidate for ... Female Sexual Dysfunction (FSD).  Lorexys, clinical ...
Cached Medicine Technology:Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 16S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) 2
... The R4Mplus offers global companies ... help meet RFID compliance initiatives. With ... a variety of connectivity options, and ... is a super value. Plus, the ...
... The 105SL combines enhanced memory, ... rugged and reliable all-metal construction. ... processing and print speed make ... users who value reliability, productivity, ...
... R4Mplus offers global companies a cost-effective ... RFID compliance initiatives. With die-cast metal ... of connectivity options, and complex multi-language ... super value. Plus, the fully integrated ...
... Ideal for patient wristband printing, the ... reliable and accurate scanning for improved patient ... text, and graphics on a variety of ... printer prints patient ID wristbands on demand. ...
Medicine Products: